2023
First-Line Treatment of Driver-Negative Non–Small Cell Lung Cancer
Kim S, Gettinger S. First-Line Treatment of Driver-Negative Non–Small Cell Lung Cancer. Hematology/Oncology Clinics Of North America 2023, 37: 557-573. PMID: 37150586, DOI: 10.1016/j.hoc.2023.02.008.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLung cancerAdvanced non-small cell lung cancerFirst-line settingFirst-line treatmentStandard of careCombination immunotherapyImmunotherapy monotherapyPD-L1Immunotherapy responseLine treatmentSmoking statusTreatment choiceTrial dataCancerImmunotherapyRegimensCliniciansTreatmentChemoimmunotherapyMonotherapyCare
2022
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 497-530. PMID: 35545176, DOI: 10.6004/jnccn.2022.0025.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNCCN Clinical Practice GuidelinesCell lung cancerClinical practice guidelinesLung cancerPractice guidelinesMetastatic non-small cell lung cancerMetastatic lung cancerNCCN guidelinesPrimary treatmentTargeted therapyActionable mutationsPatientsCancerSubsequent treatmentTherapyOncologyTreatmentGuidelinesImmunotherapyRelapseDiagnosis
2011
A Decade of Advances in Treatment for Advanced Non–Small Cell Lung Cancer
Gettinger S, Lynch T. A Decade of Advances in Treatment for Advanced Non–Small Cell Lung Cancer. Clinics In Chest Medicine 2011, 32: 839-851. PMID: 22054890, DOI: 10.1016/j.ccm.2011.08.017.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerLung cancerEpidermal growth factor receptor (EGFR) mutational statusProspective randomized clinical trialsRandomized clinical trialsClinical characteristicsClinical trialsTraditional chemotherapyMutational statusTherapyHistologyCancerHomogeneous populationTreatmentChemotherapyPatientsDecades of advancesTrialsBiomarkers
2010
Targeted therapy for thyroid cancer: An updated review of investigational agents.
Deshpande HA, Gettinger SN, Sosa JA. Targeted therapy for thyroid cancer: An updated review of investigational agents. Current Opinion In Investigational Drugs 2010, 11: 661-8. PMID: 20496261.Peer-Reviewed Original ResearchConceptsMedullary thyroid cancerThyroid cancerEarly phase clinical trialsPapillary thyroid cancerRandomized trialsInvestigational agentsClinical trialsTargeted therapyPotential therapyPromising drugXL-184CancerTreatmentUpdated reviewTherapyTrialsMolecular mechanismsSunitinibMalignancySorafenibVandetanibBRAFVEGFRCarcinogenesis
2007
Treatment of Lung Cancer in Older Patients
Tanoue LT, Gettinger S. Treatment of Lung Cancer in Older Patients. Clinics In Chest Medicine 2007, 28: 735-749. PMID: 17967291, DOI: 10.1016/j.ccm.2007.08.003.Peer-Reviewed Original Research